Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of oral orforglipron in Japanese adults with obesity
jRCT2031230221Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Mean Percent Change in Body Weight and Proportion of participants achieving ≥5% body weight reduction. Started Jul 2023; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2031230221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230221.